Modeling the evolution of the US opioid crisis for national policy development
Tse Yang Lim(United States Food and Drug Administration), Mohammad S. Jalali(Polytechnical University of Kabul), Sara Eggers(United States Food and Drug Administration), Calvin B. Bannister(United States Food and Drug Administration), Wayne Wakeland(Portland State University), Keith Humphreys(Stanford Medicine), Celia Stafford(Harvard University), Erin J. Stringfellow(Harvard University), Lukas Glos(United States Food and Drug Administration), Emily G. Ewing(United States Food and Drug Administration), Reza Kazemi(University of Tehran), Jack Homer(Barry University), Douglas C. Throckmorton(United States Food and Drug Administration), Catherine DiGennaro(Harvard University)
Cited by 94
Related Papers
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
|Clinical Pharmacology & Therapeutics|2007|582
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
|Nature Biotechnology|2010|406
PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products
|Kidney International|1995|174
Activation-induced apoptosis in human macrophages: developmental regulation of a novel cell death pathway by macrophage colony-stimulating factor and interferon gamma.
|The Journal of Experimental Medicine|1995|172
Health Care and Cybersecurity: Bibliometric Analysis of the Literature
|Journal of Medical Internet Research|2018|133